Skip to main content

Editorial Board

Albert Jeltsch, PhD, University of Stuttgart, Germany
Founding Editors
Frank Grosveld, PhD, Erasmus University Medical Center, The Netherlands
Steve Henikoff, PhD, Fred Hutchinson Cancer Center, United States of America
Associate Editor
Tamas Aranyi, MD, PhD, HUN-REN, Research Centre for Natural Sciences, Hungary and Semmelweis University, Hungary
Editorial Board
Julie Ahringer, PhD, FRS, FMedSci, Gurdon Institute, University of Cambridge, United Kingdom
Juan Ausió, BSc, PhD, University of Victoria, Canada
Tuncay Baubec, PhD, Utrecht University, The Netherlands
Shelley Berger, PhD, University of Pennsylvania, United States of America
Timothy Bestor, PhD, Columbia University, United States of America 
Yamini Dalal, PhD, National Cancer Institute, United States of America 
Elzo de Wit, PhD, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, The Netherlands
Pierre-Antoine DefossezPhD, Université Paris Cité, France
Jerome Dejardin, PhD, Institute of Human Genetics, France
Anne Ferguson-Smith, PhD, CBE, FRS, FMedSci, University of Cambridge, United Kingdom
Amanda Fisher, PhD, Imperial College London, United Kingdom
John Greally, PhD, DMed, MB, BCh, BAO, Albert Einstein College of Medicine, United States of America
Shiv Grewal, PhD, National Institutes of Health, United Kingdom
Joost Gribnau, Erasmus University Medical Center, Netherlands
Frank Grosveld, PhD, Erasmus University Medical Center, The Netherlands
Gordon Hager, PhD, National Cancer Institute, United States of America
Steve Henikoff, PhD, Fred Hutchinson Cancer Center, United States of America
Steven Jacobsen, PhD, University of California, Los Angeles, United States of America
Paul Kaufman, PhD, University of Massachusetts Chan Medical SchoolUnited States of America
William Kelly, PhD, Emory University, United States of America
Siavash Kurdistani, MD, University of California, Los Angeles, United States of America
Colin Logie, PhD, Radboud University Nijmegen Medical Centre, The Netherlands
Frank Lyko, PhD, German Cancer Research Center, Germany
Kazuhiro Maeshima, PhD, National Institute of Genetics, Japan
Valerio Orlando, PhD, King Abdullah University of Science and Technology, Saudi Arabia
Vincenzo Pirotta, PhD, Rutgers University, United States of America
Ana Pombo, PhD, Max Delbrück Center for Molecular Medicine, Germany
Oliver Rando, PhD, University of Massachusetts Chan Medical SchoolUnited States of America
Wendy Robinson, PhD, BC Children's Hospital Foundation, Canada
Yang Shi, PhD, Ludwig Cancer Research, United Kingdom
David Spector, PhD, Cold Spring Harbor Laboratory, United States of America 
Yoichi Shinkai, PhD, RIKEN, Japan
Brian Strahl, PhD, University of North Carolina SystemUnited States of America 
Azim Surani, PhD, The Wellcome Trust, Cancer Research, United Kingdom
David Tremethick, PhD, Australian National University, Australia
Jessica Tyler, PhD, MD Banner MD Anderson Cancer CenterUnited States of America 
Bas van Steensel, PhD, Netherlands Cancer Institute, Netherlands
Dr. rer nat. Jörn Walter, Saarland University, Germany
Jerry Workman, PhD, Stowers Institute for Medical Research, United States of America 
Anton Wutz, PhD, ETH Zurich, Switzerland
Rui-ming Xu, PhD, Chinese Academy of Sciences, China
Yi Zhang, PhD, Harvard Medical School, Harvard University, United States of America 

Affiliated with

  • Epigenetics & Chromatin is affiliated with the International Society for Molecular and Clinical Epigenetics (isMOCLEP). isMOCLEP is open to all those interested in the wide spectrum of epigenetic research, from molecular to clinical aspects. isMOCLEP community welcomes academic researchers, early career scientists, companies, policy makers, and beyond.

Annual Journal Metrics

  • 2022 Citation Impact
    3.9 - 2-year Impact Factor
    5.1 - 5-year Impact Factor
    1.097 - SNIP (Source Normalized Impact per Paper)
    2.586 - SJR (SCImago Journal Rank)

    2023 Speed
    2 days submission to first editorial decision for all manuscripts (Median)
    76 days submission to accept (Median)

    2023 Usage 
    307 Altmetric mentions